Copyright Reports & Markets. All rights reserved.

Global Angiotensin Receptor Blockers (ARBs) Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Angiotensin Receptor Blockers (ARBs) Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Angiotensin Receptor Blockers (ARBs) Market Size Growth Rate by Product
      • 1.4.2 Valsartan
      • 1.4.3 Telmisartan
      • 1.4.4 Losartan
      • 1.4.5 Irbesartan
      • 1.4.6 Azilsartan
      • 1.4.7 Olmesartan
    • 1.5 Market by End User
      • 1.5.1 Global Angiotensin Receptor Blockers (ARBs) Market Size Growth Rate by End User
      • 1.5.2 Hypertension
      • 1.5.3 Cardiovascular Diseases
      • 1.5.4 Kidney Diseases
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Angiotensin Receptor Blockers (ARBs) Market Size
      • 2.1.1 Global Angiotensin Receptor Blockers (ARBs) Revenue 2014-2025
      • 2.1.2 Global Angiotensin Receptor Blockers (ARBs) Sales 2014-2025
    • 2.2 Angiotensin Receptor Blockers (ARBs) Growth Rate by Regions
      • 2.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Regions
      • 2.2.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Angiotensin Receptor Blockers (ARBs) Sales by Manufacturers
      • 3.1.1 Angiotensin Receptor Blockers (ARBs) Sales by Manufacturers
      • 3.1.2 Angiotensin Receptor Blockers (ARBs) Sales Market Share by Manufacturers
      • 3.1.3 Global Angiotensin Receptor Blockers (ARBs) Market Concentration Ratio (CR5 and HHI)
    • 3.2 Angiotensin Receptor Blockers (ARBs) Revenue by Manufacturers
      • 3.2.1 Angiotensin Receptor Blockers (ARBs) Revenue by Manufacturers (2014-2019)
      • 3.2.2 Angiotensin Receptor Blockers (ARBs) Revenue Share by Manufacturers (2014-2019)
    • 3.3 Angiotensin Receptor Blockers (ARBs) Price by Manufacturers
    • 3.4 Angiotensin Receptor Blockers (ARBs) Manufacturing Base Distribution, Product Types
      • 3.4.1 Angiotensin Receptor Blockers (ARBs) Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Angiotensin Receptor Blockers (ARBs) Product Type
      • 3.4.3 Date of International Manufacturers Enter into Angiotensin Receptor Blockers (ARBs) Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Product
    • 4.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Product
    • 4.3 Angiotensin Receptor Blockers (ARBs) Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Angiotensin Receptor Blockers (ARBs) Breakdown Data by End User

    6 North America

    • 6.1 North America Angiotensin Receptor Blockers (ARBs) by Countries
      • 6.1.1 North America Angiotensin Receptor Blockers (ARBs) Sales by Countries
      • 6.1.2 North America Angiotensin Receptor Blockers (ARBs) Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Angiotensin Receptor Blockers (ARBs) by Product
    • 6.3 North America Angiotensin Receptor Blockers (ARBs) by End User

    7 Europe

    • 7.1 Europe Angiotensin Receptor Blockers (ARBs) by Countries
      • 7.1.1 Europe Angiotensin Receptor Blockers (ARBs) Sales by Countries
      • 7.1.2 Europe Angiotensin Receptor Blockers (ARBs) Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Angiotensin Receptor Blockers (ARBs) by Product
    • 7.3 Europe Angiotensin Receptor Blockers (ARBs) by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Angiotensin Receptor Blockers (ARBs) by Countries
      • 8.1.1 Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales by Countries
      • 8.1.2 Asia Pacific Angiotensin Receptor Blockers (ARBs) Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Angiotensin Receptor Blockers (ARBs) by Product
    • 8.3 Asia Pacific Angiotensin Receptor Blockers (ARBs) by End User

    9 Central & South America

    • 9.1 Central & South America Angiotensin Receptor Blockers (ARBs) by Countries
      • 9.1.1 Central & South America Angiotensin Receptor Blockers (ARBs) Sales by Countries
      • 9.1.2 Central & South America Angiotensin Receptor Blockers (ARBs) Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Angiotensin Receptor Blockers (ARBs) by Product
    • 9.3 Central & South America Angiotensin Receptor Blockers (ARBs) by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Angiotensin Receptor Blockers (ARBs) by Countries
      • 10.1.1 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales by Countries
      • 10.1.2 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Angiotensin Receptor Blockers (ARBs) by Product
    • 10.3 Middle East and Africa Angiotensin Receptor Blockers (ARBs) by End User

    11 Company Profiles

    • 11.1 Pfizer
      • 11.1.1 Pfizer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Pfizer Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Pfizer Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.1.5 Pfizer Recent Development
    • 11.2 Novartis
      • 11.2.1 Novartis Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Novartis Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Novartis Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.2.5 Novartis Recent Development
    • 11.3 Merck
      • 11.3.1 Merck Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Merck Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Merck Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.3.5 Merck Recent Development
    • 11.4 Astra Zeneca
      • 11.4.1 Astra Zeneca Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.4.5 Astra Zeneca Recent Development
    • 11.5 Jhonson and Johnson
      • 11.5.1 Jhonson and Johnson Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.5.5 Jhonson and Johnson Recent Development
    • 11.6 Eli Lilly
      • 11.6.1 Eli Lilly Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Eli Lilly Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.6.5 Eli Lilly Recent Development
    • 11.7 Sanofi
      • 11.7.1 Sanofi Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Sanofi Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Sanofi Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.7.5 Sanofi Recent Development
    • 11.8 Bristol-Myers Squibb
      • 11.8.1 Bristol-Myers Squibb Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.8.5 Bristol-Myers Squibb Recent Development
    • 11.9 Bayer
      • 11.9.1 Bayer Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Bayer Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Bayer Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.9.5 Bayer Recent Development
    • 11.10 GSK
      • 11.10.1 GSK Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 GSK Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 GSK Angiotensin Receptor Blockers (ARBs) Products Offered
      • 11.10.5 GSK Recent Development
    • 11.11 Teva Pharmaceutical

    12 Future Forecast

    • 12.1 Angiotensin Receptor Blockers (ARBs) Market Forecast by Regions
      • 12.1.1 Global Angiotensin Receptor Blockers (ARBs) Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Angiotensin Receptor Blockers (ARBs) Revenue Forecast by Regions 2019-2025
    • 12.2 Angiotensin Receptor Blockers (ARBs) Market Forecast by Product
      • 12.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales Forecast by Product 2019-2025
      • 12.2.2 Global Angiotensin Receptor Blockers (ARBs) Revenue Forecast by Product 2019-2025
    • 12.3 Angiotensin Receptor Blockers (ARBs) Market Forecast by End User
    • 12.4 North America Angiotensin Receptor Blockers (ARBs) Forecast
    • 12.5 Europe Angiotensin Receptor Blockers (ARBs) Forecast
    • 12.6 Asia Pacific Angiotensin Receptor Blockers (ARBs) Forecast
    • 12.7 Central & South America Angiotensin Receptor Blockers (ARBs) Forecast
    • 12.8 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Angiotensin Receptor Blockers (ARBs) Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Angiotensin II receptor blockers (ARBs), also known as angiotensin II receptor antagonists, AT1 receptor antagonists or sartans, are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
      The global Angiotensin Receptor Blockers (ARBs) market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Angiotensin Receptor Blockers (ARBs) market based on company, product type, end user and key regions.

      This report studies the global market size of Angiotensin Receptor Blockers (ARBs) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Angiotensin Receptor Blockers (ARBs) in these regions.
      This research report categorizes the global Angiotensin Receptor Blockers (ARBs) market by top players/brands, region, type and end user. This report also studies the global Angiotensin Receptor Blockers (ARBs) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Pfizer
      Novartis
      Merck
      Astra Zeneca
      Jhonson and Johnson
      Eli Lilly
      Sanofi
      Bristol-Myers Squibb
      Bayer
      GSK
      Teva Pharmaceutical

      Market size by Product
      Valsartan
      Telmisartan
      Losartan
      Irbesartan
      Azilsartan
      Olmesartan
      Market size by End User
      Hypertension
      Cardiovascular Diseases
      Kidney Diseases
      Other

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Angiotensin Receptor Blockers (ARBs) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Angiotensin Receptor Blockers (ARBs) market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Angiotensin Receptor Blockers (ARBs) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Angiotensin Receptor Blockers (ARBs) submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Angiotensin Receptor Blockers (ARBs) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Angiotensin Receptor Blockers (ARBs) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now